International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 (WCLC 2023)

In the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation, the combination of osimertinib plus pemetrexed and platinum-based chemotherapy outperformed osimertinib alone in terms of extending progression-free survival (PFS), according to the interim results of the phase III FLAURA2 trial presented at WCLC 2023.

Immune-related adverse events (irAEs) are more likely to develop in metastatic nonsmall cell lung cancer (NSCLC) patients with certain prognostic characteristics, suggests a study. Interestingly, those who develop irAEs benefit from a much longer overall survival (OS) and time to next treatment when mitigating immortal time bias.

Treatment with canakinumab appears beneficial to patients with advanced nonsmall cell lung cancer (NSCLC) with low T-cell infiltration (ie, low total count or immune desert phenotype), results of predefined exploratory biomarker analyses from the CANOPY-1 have shown.

Patients with previously untreated, locally advanced, or metastatic squamous non-small-cell lung cancer (NSCLC) may derive benefit from the addition of the novel anti-PD-1 monoclonal antibody serplulimab to chemotherapy, according to the final analysis of the phase III ASTRUM-004 study.

In the phase III INSPIRE study, the novel, potent ALK tyrosine kinase inhibitor (TKI) iruplinalkib conferred a progression-free survival (PFS) benefit in patients with TKI-naïve, locally advanced, or metastatic ALK+ non-small-cell lung cancer (NSCLC).

In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).